Ligand Pharmaceuticals
LGND
184 hedge funds and large institutions have $1.4B invested in Ligand Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 69 increasing their positions, 62 reducing their positions, and 16 closing their positions.
138% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 16
29% more capital invested
Capital invested by funds: $1.09B → $1.4B (+$312M)
12% more funds holding
Funds holding: 165 → 184 (+19)
11% more call options, than puts
Call options by funds: $23.7M | Put options by funds: $21.3M
11% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 62
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
TAMRO Capital Partners
Alexandria,
Virginia
|
+$20.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.3M |
| 3 |
CCI
Columbus Circle Investors
|
+$19.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$7.21M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$7.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$35.4M |
| 2 |
William Blair & Company
Chicago,
Illinois
|
-$17.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.9M |
| 4 |
ACMM
Arbor Capital Management (Minnesota)
Minneapolis,
Minnesota
|
-$7.94M |
| 5 |
GP
Grow Partners
San Diego,
California
|
-$7.86M |
LGND Hedge Fund Activity: Q1 2014 in Review
184 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2014, worth a combined $1.4B — up 29% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new LGND positions and 16 closed out — a net gain of 22 holders — while 69 added to existing stakes and 62 trimmed.
The largest buyer was TAMRO Capital Partners, opening a new position worth an estimated $20.8M. The largest seller was BVF Inc, cutting an estimated $35.4M.
- 184 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2014, up from 165 in Q4 2013.
- Funds reported $1.4B of Ligand Pharmaceuticals stock for Q1 2014, up 29% quarter-over-quarter.
- 38 funds opened new Ligand Pharmaceuticals positions in Q1 2014 and 16 closed out, a net change of +22 holders.
- The largest Ligand Pharmaceuticals buyer in Q1 2014 was TAMRO Capital Partners, an estimated $20.8M added.
- The largest Ligand Pharmaceuticals seller in Q1 2014 was BVF Inc, an estimated $35.4M sold.
Based on aggregated 13F filings for Q1 2014.